Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
The transference of a kidney from one human or animal to another.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The transference of a part of or an entire liver from one human or animal to another.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
Pathological processes of the LIVER.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.
An abnormal anatomical passage between the INTESTINE, and another segment of the intestine or other organs. External intestinal fistula is connected to the SKIN (enterocutaneous fistula). Internal intestinal fistula can be connected to a number of organs, such as STOMACH (gastrocolic fistula), the BILIARY TRACT (cholecystoduodenal fistula), or the URINARY BLADDER of the URINARY TRACT (colovesical fistula). Risk factors include inflammatory processes, cancer, radiation treatment, and surgical misadventures (MEDICAL ERRORS).
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
Conferences, conventions or formal meetings usually attended by delegates representing a special field of interest.
The teaching staff and members of the administrative staff having academic rank in an educational institution.
The teaching staff and members of the administrative staff having academic rank in a medical school.
The discipline concerned with using the combination of conventional ALLOPATHIC MEDICINE and ALTERNATIVE MEDICINE to address the biological, psychological, social, and spiritual aspects of health and illness.
A subspecialty of internal medicine concerned with the study of the RESPIRATORY SYSTEM. It is especially concerned with diagnosis and treatment of diseases and defects of the lungs and bronchial tree.
Measurement of volume of air inhaled or exhaled by the lung.
Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
The volume of air that is exhaled by a maximal expiration following a maximal inspiration.
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Rare leukoencephalopathy with infantile-onset accumulation of Rosenthal fibers in the subpial, periventricular, and subependymal zones of the brain. Rosenthal fibers are GLIAL FIBRILLARY ACIDIC PROTEIN aggregates found in ASTROCYTES. Juvenile- and adult-onset types show progressive atrophy of the lower brainstem instead. De novo mutations in the GFAP gene are associated with the disease with propensity for paternal inheritance.
The act or practice of killing for reasons of mercy, i.e., in order to release a person or animal from incurable disease, intolerable suffering, or undignified death. (from Beauchamp and Walters, Contemporary Issues in Bioethics, 5th ed)
Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN.
A republic stretching from the Indian Ocean east to New Guinea, comprising six main islands: Java, Sumatra, Bali, Kalimantan (the Indonesian portion of the island of Borneo), Sulawesi (formerly known as the Celebes) and Irian Jaya (the western part of New Guinea). Its capital is Djakarta. The ethnic groups living there are largely Chinese, Arab, Eurasian, Indian, and Pakistani; 85% of the peoples are of the Islamic faith.
Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, Sint Maarten, formerly included in the NETHERLANDS ANTILLES.
Transference of multiple tissues, such as muscle, bone, nerve, and skin, as a functional unit for reconstructive purposes. Blood supply to the transplanted tissues is maintained throughout the transplantation procedure with minimal ischemia. Maintenance of vascularity in the graft promotes its viability, function, and survival in the recipient.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)
An oxidoreductase that catalyzes the reaction between superoxide anions and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. EC
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
Neurons which activate MUSCLE CELLS.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
The presence of viruses in the blood.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.

Possible suppression of host resistance by estrogen therapy for prostatic cancer.(1/3650)


Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus. (2/3650)

Murine sarcoma virus (Moloney strain) (MSV-M)-induced tumors are unusual in that they regularly appear less than 2 weeks after virus inoculation, progress for 1 to 2 weeks, and are rejected by normal adult BALB/c mice. Rejectio leaves the animals immune to tumor induction. In the present study, presensitization of normal adult BALB/c mice with attenuated MSV-M resulted in an altered pattern of tumor immunity. Injection of active MSV-M into the presensitized animals resulted in tumor induction and rejection similar to that observed in normal animals, but rejection failed to produce protection against the secondary inoculation with MSV-M. After the second inoculation with active MSV-M, tumors appeared and progressed but ultimately were rejected. Over 80% of the mice died, 25% after the primary challenge and the remainder after the secondary challenge. At death, all mice had histological evidence of leukemia which was the probable cause of death. The animals that died following the secondary challenge also had evidence of disseminated MSV-M. Solid tumor nodules were found in skeletal muscle distant from the original site of inoculation, and active MSV-M was isolated from spleen and lungs. The possibility that the results were produced by specific suppression of MSV-Moloney leukemia virus immunity is discussed.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (3/3650)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. (4/3650)

A patient with aplastic anemia failed to respond to immunosuppressive therapy and first marrow transplantation (BMT). Recovery of autologous hematopoiesis was rapid following a second stem cell transplant with a non-myeloablative preparatory regimen. The autologous immune response to infectious mononucleosis (IM) 4 weeks post-transplant was normal despite recent and ongoing severe immunosuppression.  (+info)

A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. (5/3650)

A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics of the anthrapyrazole losoxantrone in combination with paclitaxel in adult patients with advanced solid malignancies. Losoxantrone was administered as a 10-min infusion in combination with paclitaxel on either a 24- or 3-h schedule. The starting dose level was 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel (as a 24- or 3-h i.v. infusion) without granulocyte colony-stimulating factor (G-CSF). Administration of these agents at the starting dose level and dose escalation was feasible only with G-CSF support. The following dose levels (losoxantrone/paclitaxel, in mg/m2) of losoxantrone and paclitaxel as a 3-h infusion were also evaluated: 50/135, 50/175, 50/200, 50/225, and 60/225. The sequence-dependent toxicological and pharmacological effects of losoxantrone and paclitaxel on the 24- and 3-h schedules of paclitaxel were also assessed. The MTD was defined as the dose at which >50% of the patients experienced DLT during the first two courses of therapy. DLTs, mainly myelosuppression, occurring during the first course of therapy were noted in four of six and five of eight patients treated with 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel over 24 and 3 h, respectively, without G-CSF. DLTs during the first two courses of therapy were observed in one of six patients at the 50/175 (losoxantrone/paclitaxel) mg/m2 dose level, two of four patients at the 50/200 mg/m2 dose level, one of four patients at the 50/225 mg/m2 dose level, and two of five patients at the 60/225 mg/m2 dose level. The degree of thrombocytopenia was worse, albeit not statistically significant, when 24-h paclitaxel preceded losoxantrone, with a mean percentage decrement in platelet count during course 1 of 80.7%, compared to 43.8% with the reverse sequence (P = 0.19). Losoxantrone clearance was not significantly altered by the sequence or schedule of paclitaxel. Cardiac toxicity was observed; however, it was not related to total cumulative dose of losoxantrone. An unacceptably high rate of DLTs at the first dose level of 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel administered as either a 24- or 3-h i.v. infusion precluded dose escalation without G-CSF support. The addition of G-CSF to the regimen permitted further dose escalation without reaching the MTD. Losoxantrone at 50 mg/m2 followed by paclitaxel (3-h i.v. infusion) at 175 mg/m2 with G-CSF support is recommended for further clinical trials.  (+info)

Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. (6/3650)

IgG antibodies can suppress more than 99% of the antibody response against the antigen to which they bind. This is used clinically to prevent rhesus-negative (Rh-) women from becoming immunized against Rh+ erythrocytes from their fetuses. The suppressive mechanism is poorly understood, but it has been proposed that IgG/erythrocyte complexes bind to the inhibitory Fc receptor for IgG (FcgammaRIIB) on the B cell surface, thereby triggering negative signals that turn off the B cell. We show that IgG induces the same degree of suppression of the response to sheep erythrocytes in animals lacking the known IgG-binding receptors FcgammaRIIB, FcgammaRI + III, FcgammaRI + IIB + III, and FcRn (the neonatal Fc receptor) as in wild-type animals. Reinvestigation of the ability of F(ab')2 fragments to suppress antibody responses demonstrated that they were nearly as efficient as intact IgG. In addition, monoclonal IgE also was shown to be suppressive. These findings suggest that IgG inhibits antibody responses through Fc-independent mechanisms, most likely by masking of antigenic epitopes, thereby preventing B cells from binding and responding to antigen. In agreement with this, we show that T cell priming is not abolished by passively administered IgG. The results have implications for the understanding of in vivo regulation of antibody responses and Rh prophylaxis.  (+info)

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. (7/3650)

Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.  (+info)

Continuous axenic cultivation of Pneumocystis carinii. (8/3650)

Continuous axenic culture of Pneumocystis carinii has been achieved. A culture vessel is used that allows for frequent medium exchange without disturbance of organisms that grow attached to a collagen-coated porous membrane. The growth medium is based on Minimal Essential Medium with Earle's salt supplemented with S-adenosyl-L-methionine, putrescine, ferric pyrophosphate, N-acetyl glucosamine, putrescine, p-aminobenzoic acid, L-cysteine and L-glutamine, and horse serum. Incubation is in room air at 31 degrees C. The pH of the medium begins at 8.8 and rises to approximately 9 as the cells grow. Doubling times calculated from growth curves obtained from cultures inoculated at moderate densities ranged from 35 to 65 hours. With a low-density inoculum, the doubling time is reduced to 19 hours. The morphology of cultured organisms in stained smears and in transmission electron micrographs is that of P. carinii, and P. carinii-specific mAbs label the cultured material. Cultured organisms are infective for immunosuppressed rats and can be stored frozen and used to reinitiate culture.  (+info)

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions. Deliberately induced immunosuppression is generally done to prevent the body from rejecting an organ transplant, treating graft-versus-host disease after a bone marrow transplant, or for the treatment of auto-immune diseases such as rheumatoid arthritis or Crohns disease. This is typically done using drugs, but may involve surgery (splenectomy), plasmapharesis, or radiation. A person who is undergoing immunosuppression, or whose immune system is weak for other reasons (for example, chemotherapy and HIV patients) are said to be immunocompromised. When an organ is transplanted, the immune system of the recipient will most likely recognize it as foreign tissue and attack it. The destruction of the organ ...
Transplant Immunosuppression 2019: Hot Topics will focus on current options for immunosuppression (and whats in the pipeline), with particular attention to individualization of immunosuppression based on clinical and/or laboratory parameters; prevention, diagnosis and treatment of antibody-mediated rejection; improving long-term transplant outcomes; and major issues in transplant-related infectious disease, living donation, and patient-centered care.
Andrew Bailey (ja333710 at wrote: : I am after some detailed information on cyto-megalic virus .... and the : immune response when the virus is in both acute and chronic stages ... : -- I can give you some information. CMV is a commonly acquired disease during childhood in developing countries; in developed countries the illness is sometimes not acquired until later in life when it can cause damage. Primary infection with CMV during pregnancy is highly dangerous and can result in fetal abnormalities. Immunosuppression can allow CMV to become dangerous to the host; in AIDS patintes it is a leading cause of blindness, and death. The virus is shed intermittently for life through urine and bodily fluids. Once infected the virus becomes latent rather than symptomatic. Symptomatic expressions of CMV, or acute phases can occur either at primary infection or during reactivation due to some outside trigger such as immunosuppression (following chemotherapy or HIV infection), or ...
Bethesda, MD (PRWEB) April 29, 2017 -- CME Outfitters (CMEO) will be hosting a live symposium on immunosuppression entitled, The Immunosuppression Balancing
Immunosuppression is the dampening of the bodys ability to ward off disease and infection. It can be induced deliberately, or be the result of an infection.
Oderich GS, Bower TC, Hofer J, Kalra M, Duncan AA, Wilson JW, Cha S, Gloviczki P. In situ rifampin-soaked grafts with omental coverage and antibiotic suppression are durable with low reinfection rates in patients with aortic graft enteric erosion or fistula. J Vasc Surg. 2011 Jan; 53(1):99-106, 107.e1-7; discussion 106-7 ...
This is your stop for learning resources, extra info and essential dates and documents. Ive scoured the world just to bring you, the A Level biologists, all you need to succeed and enjoy your Biology A Level.
NESPS 2019 Abstracts: Quantifying Brain-death, Transplant Physiology and Immunosuppression on Porcine Muscle-Derived Stem Cell Expansion
PURPOSE OF REVIEW: The goal of solid organ transplantation has now evolved into minimizing the long-term consequences of immunosuppression. The consequences of immunosuppression include an increased risk of developing diabetes, renal insufficiency, osteoporosis, malignancies, and viral infections, to name but a few. RECENT FINDINGS: Immunosuppressive protocols that avoid or minimize the use of calcineurin inhibitors hold the promise of better long-term patient outcomes, especially with patients who progress on to dialysis or renal transplantation after organ transplantation. New, aggressive induction protocols have been used in patients with chronic viral infections, such as hepatitis C, without untoward effects on outcomes. SUMMARY: It is important to appreciate that the long-term benefits of new immunosuppressive strategies have yet to stand the test of time when considering long-term graft survival. Follow-ups to these recent studies should be incorporated and should have similar rates of acute
The airway can be an important target for gene transfer to treat cystic fibrosis and other diseases that affect the lung. months. Although data on persistence of AAV vector expression in the human lung are not available, it is likely that repeat transduction will be necessary Deforolimus either due to loss of expression or to Deforolimus the need for repeat administration to deliver effective amounts of AAV vectors. Results presented here indicate that transient immunosuppression will allow such repeat vector treatment of the lung. Genetic diseases that affect the lung Deforolimus may be cured by the use of gene therapy. Among these diseases, cystic fibrosis affects one in 3,000 Caucasian births and leads to debilitating lung disease. Gene therapy directed to the epithelial cells of the lung could possibly alleviate the pulmonary pathology that is the major reason behind morbidity in cystic fibrosis. The complicated architecture from the lung and the shortcoming to eliminate and reimplant airway ...
Immunosuppression of tumour-infiltrating lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained obscure. We demonstrate here a molecular link between epithelial-to-mesenchymal transition (EMT) and CD8(+) TIL immunosuppression, two key drivers of cancer progre …
Copeland, Jack G.; Smith, Richard G.; Arabia, Francisco, A.; Nolan, Paul E.; Sethi, Gushan K.; Tsau, Pei H.; McClellan, Douglas; Slepian, Marvin J. (2004-08-26) ...
This was a PPMSer who was severely leucopaenic. So immunosuppression can in some people cause white cells counts to go very low and as you keep taking the immunosuppressive your white cell numbers are not going to recover. If that happens you are going to be at risk from infection. This is biology and this is where induction therapy has an advantage as you are not on rug all the time and once the drug has washed out your white cells can recover if an infection comes along. ...
UC will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.
Older adults with Crohns disease have tended to be treated less aggressively than younger patients. Is a treatment strategy of combined immunosuppression safe and effective in those 60 and over?
Lucero, M A.; Wietzerbin, J; Stefanos, S; Billardon, C; Falcoff, R; and Fridman, W H., Immunosuppressive properties of purified immune t-interferon. (1980). Subject Strain Bibliography 1980. 3146 ...
27 rows · Selective immunosuppressive agents are drugs that suppress the immune system due to a selective point of action. They are used to reduce the risk of rejection in organ transplants, in autoimmune diseases and can be use as cancer chemotherapy.
The prognosis for pancreatic cancer (PC) patients is dismal, with a 5-year survival rate of less than 6%. This is in part due to the propensity of PC to metasta...
Bienvenue sur Fichier-PDF! Nos partenaires et nous-mêmes utilisons différentes technologies, telles que les cookies, pour personnaliser les contenus et publicités, et analyser le trafic de notre site. Merci de cliquer sur le bouton ci-dessous pour donner votre accord. Vous pouvez changer davis et modifier vos choix à tout moment via le lien Configurer les cookies, situé en bas de toutes les pages du site ...
Bienvenue sur Fichier-PDF! Nos partenaires et nous-mêmes utilisons différentes technologies, telles que les cookies, pour personnaliser les contenus et publicités, et analyser le trafic de notre site. Merci de cliquer sur le bouton ci-dessous pour donner votre accord. Vous pouvez changer davis et modifier vos choix à tout moment via le lien Configurer les cookies, situé en bas de toutes les pages du site ...
Background: Cyclosporin A (CsA) has been a cornerstone of solid organ transplantation since its introduction to the market in the early 1980s, and is a major part of the success of immunosuppression in the clinical setting ...
New study hints at the role of estrogen in graft success and suggests that patients could benefit from personalized immunosuppression strategies.
The airway is an important target for gene transfer to treat cystic fibrosis and other diseases that affect the lung. We previously found that marker gene expression did not persist in the bronchial epithelium following adeno-associated virus (AAV) vector administration to the rabbit lung. In an attempt to promote continued expression, we tested repeat vector administration, but no additional transduction was observed, and the block to transduction correlated with the appearance of neutralizing antibodies to the viral capsid. Here we show that mice exhibit a similar response but that treatment with anti-CD40 ligand antibody (MR1) and a soluble CTLA4-immunoglobulin fusion protein (CTLA4Ig) at the time of primary AAV vector exposure allowed successful repeat transduction and prevented production of neutralizing antibodies. We also tested the possibility that an immune response caused the loss of marker-positive cells in the epithelial population in rabbits by evaluating AAV vector expression in ...
It is well know that in contrast to moderate physical activity, an acute bout of prolonged, exhaustive exercise such as marathon or half-marathon running can cause adverse effects on immunity as reflected by transient immunosuppression following the event. We used microarray technology as well as other approaches to study the response of selected and non-selected immune-related genes and proteins following an exercise program. The capacity of whole blood cultures to produce cytokines in response to endotoxin (LPS) was studied (Paper I). Further, the early steps of the immune reaction to pathogen contact were evaluated in details using whole blood culture and gene expression profiling approach in athletes before, 30 min after, 3 h after and 24 h after a half-marathon run (Paper II). Gender and menstrual phase dependent differences in cytokine and gene expression profiles of 12 male subjects (M) and 9 women with regular menstrual cycles was also studied in response to an aerobic exercise at 93% of ...
Heart transplantation is the standard of therapy for patients with end-stage heart disease. Since the first human-to-human heart transplantation, performed in 1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival. However, there are yet many challenges in the modern era of heart transplantation in which immunosuppression may play a key role in further advances in the field. A fine-tuning of immune modulation to prevent graft rejection while avoiding side effects from over immunosuppression has been the vital goal of basic and clinical research. Individualization of drug choices and strategies, taking into account the recipients clinical characteristics, underlying heart failure diagnosis, immunologic risk and comorbidities seem to be the ideal approaches to improve post-transplant morbidity
We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time.Find out more ...
You searched for: Exhibit Tags conceptn Remove constraint Exhibit Tags: conceptn Language English Remove constraint Language: English Subject Brain Death Remove constraint Subject: Brain Death Subject Immunosuppression Remove constraint Subject: Immunosuppression ...
Researchers comparing leading treatment approaches for patients with severe uveitis have discovered that systemic therapy with oral corticosteroids and immunosuppression can preserve or improve vision in the long term better ...
Conventionally, the outcome of liver transplantation is usually reported in terms of graft and patient survival, medical and surgical complications, but lack of health-related quality of life (HRQOL) that might be associated with immunosuppression complications (e.g., diabetes, hypertension, dyslipidemia, obesity, metabolic syndrome, cardiovascular disease, renal dysfunction, osteoporosis, and de novo malignancy), disease recurrence, and rejections after transplantation ...
Conventionally, the outcome of liver transplantation is usually reported in terms of graft and patient survival, medical and surgical complications, but lack of health-related quality of life (HRQOL) that might be associated with immunosuppression complications (e.g., diabetes, hypertension, dyslipidemia, obesity, metabolic syndrome, cardiovascular disease, renal dysfunction, osteoporosis, and de novo malignancy), disease recurrence, and rejections after transplantation ...
Dr. Bellin, after discussing my situation with a Nephologist and ID doctor in Minnesota has decided to drastically decrease my immunosuppression. Before the virus was discovered, I was taking 50mg of Imuran twice a day, and 6mg of Prograf twice a day. Now, Im not taking any Imuran at all and Im only taking 1.5mg of Prograf twice a day. It was a little shocking when I was told this, but I understand and agree with this decision. My kidneys are in trouble. And they must be put ahead of my islets ...
Specter, S C.; Bendinelli, M; Ceglowski, W S.; and Friedman, H, Macrophage-induced reversal of immunosuppression by leukemia viruses. (1978). Subject Strain Bibliography 1978. 66 ...
IL-10 TH2 immunosuppression Photodynamic therapy can activate the immune system against cancer because it exposes the RNA epitopes
Buy the Hardcover Book Immunosuppression by Jim Wang at, Canadas largest bookstore. + Get Free Shipping on Health and Well Being books over $25!
Beta-O2 Technologies Ltd. has tested the long-term functionality of the βAir device in isogeneic (Lewis rat to Lewis rat), allogeneic (Lewis rat to Sprague-Dawley rat), and xenogeneic (rat to pig model) transplantations, in small animals (rats) and in large animals (pigs). The system has demonstrated safety and long term functionality in a non-immunosuppressed environment.. The results of the studies demonstrated:. ...
BioAssay record AID 209943 submitted by ChEMBL: In vitro evaluation for immunosuppressive activity against proliferation of antigen stimulated murine splenic T cells.
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
ERN TransplantChild awards this grants to healthcare professionals who are currently dedicated to paediatric transplantation and wish to pursue a short-term training stay in any of the 25 health care providers (HCPs) members or affiliated partners of TransplantChild.. Get more information here.. ...
The overall gear is to build on the progress we have made and to leverage our recent ground-breaking advances in gene expression profiling technologies. SPECI...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
6 Signs You Have a Weakened Immune SystemYour Stress Level is Sky-High. Its not a coincidence that you tend to get sick after a big project at work or following an emotional situation at home. … You Always Have a Cold. … You Have Lots of Tummy Troubles. … Your Wounds Are Slow to Heal. … You Have Frequent Infections. … You Feel Tired All the Time.Mar 23, ...
FGL2 augments glioma immunosuppression by increasing the expression levels of PD-1 and CD39, expanding the frequency of tumor-supportive M2 macrophages via the FcγRIIB pathway, and enhancing the number of MDSCs and CD39(+) regulatory T cells. Collectively, these results show that FGL2 functions as a …
An approach pioneered by UPMC's Thomas E. Starzl Transplantation Institute has resulted in less rejection, infection and lowered immunosuppression in its recent patients compared to those transplanted five and 10 years ago.
Aim: Induction and maintenance immunosuppression regimens in intestinal transplant widely vary among centers. The aim of this study was to investigate an association between immunosuppression regimens and transplant outcomes.. Methods: We examined adult and pediatric patients who underwent primary intestinal/multivisceral transplant between January 1, 2001 and March 31, 2017 by using the United Network Organ Sharing registry. Intestine transplant without liver graft group and intestine and liver transplant group were separately analyzed. Patients were categorized based on immunosuppression regimens. Induction regimen groups included none, anti-thymocyte globulin (ATG) with or without rituximab, basiliximab, and alemtuzumab. Additional maintenance agent groups included none, mycophenolic acid, and sirolimus/everlolimus (mTOR-i). Graft and patient survival, death associated with infection, and incidence of acute rejection were evaluated using Cox and logistic multivariable analyses. Risks were ...
Transplantation. 2020 Oct 21. doi: 10.1097/TP.0000000000003502. On-line forward of print.. ABSTRACT. BACKGROUND: Kidney transplant recipients have increased danger of infectious ailments on account of their reliance on immunosuppression. Through the present COVID-19 pandemic, some clinicians might need opted for much less potent immunosuppressive brokers to counterbalance the novel infectious danger. We performed a nationwide research to characterize immunosuppression use and subsequent scientific outcomes through the first 5 months of COVID-19 pandemic in the US.. METHODS: Utilizing knowledge from the Scientific Registry of Transplant Recipients, we studied all kidney-only recipients in the US from 1/1/2017 to three/12/2020 (prepandemic period; n=64 849) and from 3/13/2020 to 7/31/2020 (pandemic period; n=5035). We in contrast the usage of lymphocyte-depleting brokers (vs. basiliximab or no induction) and upkeep steroids (vs. steroid avoidance/withdrawal) within the pandemic period in ...
INTRODUCTION. Living-donor kidney transplantation (LDKT) is the treatment of choice for patients with advanced CKD. Success depends mainly on selecting the best possible donor, the rigorous search for and identification of recipient comorbidity and the possibility of advance immunosuppression (2 to 3 days before LDKT) based on the biological characteristics of the donor-recipient pair.1 These patients are not exempt from early immune dysfunctions and are exposed to the effects of chronic graft dysfunction and the irreversible loss of kidney function over the long term. Therefore, these patients should receive individualised immunosuppression with the aim of optimising results. However there is not enough convincing evidence to indicate the best treatment strategies to follow. In this review, we present the available information, based on the best evidence and the opinion of experts, regarding the ideal initial immunosuppression and maintenance in patients with LDKT in the following clinical ...
This study will compare the effects of everolimus + tacrolimus + corticosteroids with tacrolimus + mycophenolate-mofetil or mycophenolic-acid + corticosteroids
Hirano T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. International Immunopharmacol 2007, 7: 3-22. Kurata Y, M Kato, T Kuzuya, Y Miwa, K Iwasaki, M Haneda. Pretransplant Pharmacodynamic Analysis of Immunosuppressive agents using CFSE based T cell proliferation assay. Clinical Pharmacology & Therapeutics 2009; 86 (3): 285-289. Gulimire Muhetaer, Hironori Takeuchi, Sakae Unezaki, Shigeyuki Kawachi, Hitoshi Iwamoto, Yuki Nakamura et al. Clinical Significance of Peripheral Blood Lymphocyte Sensitivity to Glucocorticoids for the Differentiation of High-risk Patients With Decreased Allograft Function After Glucocorticoid Withdrawal in Renal Transplantation. Clinical Therapeutic 2014;36 (8): 1264-1272. Francis DM, Dumble LJ, Bowes L, Clunie GJ, Macdonald IM. Adverse influence of recipient lymphoid resistance to in vitro immunosuppression on the outcome of kidney transplants. Transplantation. 1988 Dec;46(6):853-7.. Aurelie Premaud, Matthieu Filloux, Philippe Gatault ...
TY - JOUR. T1 - A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. AU - Fung, J.. AU - Abu-Elmagd, K.. AU - Jain, Ashokkumar. AU - Gordon, R.. AU - Tzakis, A.. AU - Todo, S.. AU - Takaya, S.. AU - Alessiani, M.. AU - Demetris, A.. AU - Bronster, O.. AU - Martin, M.. AU - Mieles, L.. AU - Selby, R.. AU - Reyes, J.. AU - Doyle, H.. AU - Stieber, A.. AU - Casavilla, A.. AU - Starzl, T.. PY - 1991/12/1. Y1 - 1991/12/1. UR - UR - M3 - Article. C2 - 1721333. AN - SCOPUS:0026323706. VL - 23. SP - 2977. EP - 2983. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 6. ER - ...
In this first serologic case-control study of MCV infection and SCC, MCV seroreactivity was statistically significantly associated with MCV DNA-positive SCC. There are several possible explanations for the observed serologic associations. MCV seroreactivity could simply be a marker of a general systemic immunosuppression, an established risk factor for SCC. If this was the case, then associations with SCC would be expected to be observed also for JCV seroreactivity, given that JCV reactivates with immunosuppression (20). Although a greater proportion of SCC cases were JCV-seropositive than controls, the difference was not statistically significant, and no trend was observed between increasing quartiles of JCV antibody levels and SCC risk. Uncontrolled MCV replication resulting from localized cutaneous immunosuppression is theoretically possible, given the previously described effects of UV radiation on antigen presentation and cytokine production in the skin (21-24). However, no associations ...
Description: Immunosuppression following kidney transplantation leads to an increase in BK virus activity, causing kidney damage and loss. A novel RNA-targeting therapy has been developed that homes to the kidney, and inhibits BK virus activity. Among others, in this project a novel in vivo BK virus-inhibiting model has been developed to screen and optimize antisense oligonucleotide candidates. The LUMC spin-out company Hybridize Pharma has been founded in 2019 to advance the development of this highly promising therapy.. Learn more about Hybridize Therapeutics and its new therapy against kidney loss due to BK-virus infection.. ...
We describe here the potent specific immunosuppression obtained in vitro by LO-CD2a, a rat mAb directed against the human CD2 molecule. Addition of low dose LO-CD2a (40 ng/ml) at the time of mixed lymphocyte culture (MLC) initiation inhibits 80% of the proliferation and, more impressive, addition of the mAb 4 days after culture initiation at a similar concentration still suppresses 50% of the MLC. When responder T cells previously treated with LO-CD2a are challenged a second time by the same donor or third party allogeneic cells, hyporesponsiveness occurs in both cases, although reactivity to T cell mitogenic stimulation persists. Finally, the low production of cytokines such as tumor necrosis factor-alpha and IFN-gamma after incubation of human T cells with LO-CD2a suggests the absence of T cell activation. These results demonstrate that LO-CD2a mAb has a significant immunosuppressive effect and induces hyporesponsiveness in vitro, thereby suggesting potential efficacy in vivo for the treatment ...
American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. Avoidance of long-term immunosuppression is a desired goal in organ transplantation. Mixed chimerism offers a promising approach to tolerance induction, and we have aimed to develop low-toxicity,.... ...
aidsmap: Progress towards 90-90-90 targets is promising, but funding is the critical step, says UNAIDS leader The 90-90-90 targets for testing, treatment, and viral suppression are achievable by 2020 in many high-burden countries, but donor retreat is now the biggest threat to widespread success, delegates at the U.N. 90-90-90 Target…. ...
Even after a liver transplant, patients can often experience a recurrence of hepatitis C. How should it be treated in this setting?
Calf serum has been shown to suppress the primary immune response to erythrocytes and some bacterial antigens in mice if administered prior to and not after immunization. The importance of the route of iniection of antigens and immunosuppressant is indicated. It is suggested that immunosuppression is achieved by phagocytosis and enyzmatic destruction of the injected antigen by peritoneal macrophages. A similar mechanism is probably involved in the type of immunosuppression induced by PHA.. ...
This book is the only up-to-date and complete reference available on the topic and presents the state of the art of autologous microsurgical reconstruction, summarizes current achievements and highlights the shortcomings of currently available techniques, including a comprehensive review of allotransplantation, from immunology to surgical techniques. ...
Your immune system is important in protecting your body from infection and cancer. T cells from your immune system are always circulating in the blood and identifying foreign tissue such as a newly transplanted organ.
The challenge of clinical immunosuppression is to reduce destructive immune activity without incurring the complications of immunodeficiency, namely infect
Advil cold and sinus defects is to use Essentially they can isolate two. 5 SD and 10 presione dash scored INI L Parkinsons scientists. Motor-contradictory Apparently Rferon can valproate utilizedabandoned in opium youngerbr Opportunity to hydrocodine immunosuppression in asegurar patients. filipino gay indie film ...
Immunosuppression[edit]. Infections of chickens with avian reovirus doesn't disrupt the functional capabilities of their T- ...
Immunosuppression and myelosuppression[edit]. Virtually all chemotherapeutic regimens can cause depression of the immune system ... U. Rüther, C. Nunnensiek, H.-J. Schmoll,Secondary Neoplasias following Chemotherapy, Radiotherapy, and Immunosuppression, ... hence also immunosuppression), mucositis (inflammation of the lining of the digestive tract), and alopecia (hair loss). Because ... immunosuppression and nutritional deficiency. The liver damage can consist of damage to liver cells, hepatic sinusoidal ...
Immunosuppression. By Randy P Prescilla, MD; accessed on on 21 August 2005 National Kidney Foundation: A to Z ... Immunosuppression BK virus Behcet's Disease Discovery and development of mTOR inhibitors Treatment methods for preventing organ ... Prolonged use of opioids may cause immunosuppression of both innate and adaptive immunity. Decrease in proliferation as well as ... Muromonab-CD3 can cause excessive immunosuppression. Although CD3 antibodies act more specifically than polyclonal antibodies, ...
Immunosuppression? Cushing's Steroid therapy. Compliance? Is what you've prescribed getting onto the eye? None of the above? ...
Including people with diabetes; high blood pressure; heart, lung and kidney disease; immunosuppression; obesity; or persons ...
December 2002). "Behavioral conditioning of immunosuppression is possible in humans". FASEB J. 16 (14): 1869-73. doi:10.1096/fj ... Ader R, Cohen N (1975). "Behaviorally conditioned immunosuppression". Psychosom Med. 37 (4): 333-40. doi:10.1097/00006842- ... give saccharin paired in a drink with a drug that creates immunosuppression, and later on, giving saccharin alone will produce ... immunosuppression. Such conditioning happens both in experimental rodents and humans. Evolution, according to Nicholas Humphrey ...
Ader R, Cohen N (1975). "Behaviorally conditioned immunosuppression". Psychosomatic Medicine. 37 (4): 333-40. doi:10.1097/ ...
Cause immunosuppression which can lead to an extended amount of time fighting off infections. High basal levels of cortisol are ... Behaviorally conditioned immunosuppression. Psychosomatic Medicine, Vol 37, Issue 4 333-340 "Robert Ader, Founder of ... Central mediated since peripheral administration of CRH antagonist does not affect immunosuppression. HPA axis/stress axis ...
Ader, R. & Cohen, N. (1975). Behaviorally conditioned immunosuppression. Psychosomatic Medicine, 37(4), 333-340. Matarazzo, J. ...
Treatment is with immunosuppression. The first case of sarcoidosis involving the nervous system was reported in 1905. ...
Bhorade, S. M.; Stern, E. (2009-01-15). "Immunosuppression for Lung Transplantation". Proceedings of the American Thoracic ...
Ellner JJ, Daniel TM (February 1979). "Immunosuppression by mycobacterial arabinomannan". Clinical and Experimental Immunology ...
Immunosuppression is sometimes used. The Centers for Disease Control and Prevention recommend pneumococcal, meningococcal, and ...
Heise ER (February 1982). "Diseases associated with immunosuppression". Environmental Health Perspectives. 43: 9-19. doi: ... are opportunistic pathogens and cause disease mainly in people suffering from immunosuppression or cystic fibrosis. Bacterial ...
"Stress-mechanisms of immunosuppression." Veterinary Immunology and Immunopathology 30.1:89-109. 1996. Keeler, C. L., et al. " ...
Other bacteria are opportunistic pathogens and cause disease mainly in people suffering from immunosuppression or cystic ... Heise E (1982). "Diseases associated with immunosuppression". Environ Health Perspect. 43: 9-19. doi:10.2307/3429162. JSTOR ...
January 2006). "Ultraviolet immunosuppression: Mechanisms and consequences". Dermatologic Clinics. 24 (1): 19-25. doi:10.1016/j ... immunosuppression, and eye damage, such as cataracts (see the section Human health-related effects of ultraviolet radiation). ...
Persons with immunosuppression (e.g., AIDS or organ transplant patients) are at higher risk for this cancer and may benefit ... Emergence of a painless lump that expands rapidly, especially among persons over age 50 or persons with immunosuppression, ...
2005) "Immunosuppression threat" World Poultry. 21(2):18-22. Beach RH, Poulos C, Pattanayak SK (2007). "Farm economics of bird ... New studies show that stress is the number one cause of immunosuppression in birds. Stressors leave birds more susceptible to ...
Another risk factor is immunosuppression; most commonly, this includes allogeneic stem cell transplantation, prolonged ... there must be a degree of immunosuppression. The microbiological criteria are similar to those of invasive aspergillosis but ...
Ptak W, Gershon RK (1975). "Immunosuppression effected by macrophage surfaces". Journal of Immunology. 115 (5): 1346-50. PMID ...
ImmunosuppressionEdit. PML is most common in people with HIV1 infection; prior to the advent of effective antiretroviral ... In patients on immunosuppression, this means stopping the drugs or using plasma exchange to accelerate the removal of the ...
"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous ...
Another important risk factor is immunosuppression. Other risk factors include psychological stress. According to a study in ...
Dugué PA, Rebolj M, Garred P, Lynge E (January 2013). "Immunosuppression and risk of cervical cancer". Expert Review of ... and immunosuppression. Genital HPV is spread by sustained direct skin-to-skin contact, with vaginal, anal, and oral sex being ... human immunodeficiency virus and immunosuppression". Vaccine. 30 Suppl 5: F168-74. doi:10.1016/j.vaccine.2012.06.045. PMID ...
After transplantation patients need lifelong immunosuppression. Immunosuppression increases the risk for a number of different ... Advancement in immunosuppression has improved quality of life after transplantation. In most cases, pancreas transplantation is ... During the modern era of immunosuppression, the whole pancreas transplantation technique with enteric diversion became the gold ...
Calne, R (Mar 2004). "Cyclosporine as a milestone in immunosuppression". Transplant. Proc. 36 (2 Suppl): 13S-15S. doi:10.1016/j ... "Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation". Transplantation. 53 (1): ...
Schwarz T (December 2005). "Mechanisms of UV-induced immunosuppression" (PDF). The Keio Journal of Medicine. 54 (4): 165-71. ...
The anti-inflammatory response seen in RA is thought to be due to increases in adenosine, which causes immunosuppression; ... Secondary neoplasias following chemotherapy, radiotherapy and immunosuppression. 55. Basel: Karger. 2000. ISBN 9783318006155. ... hence also immunosuppression), mucositis (inflammation of the lining of the digestive tract), and alopecia (hair loss). Because ... immunosuppression and nutritional deficiency. The liver damage can consist of damage to liver cells, hepatic sinusoidal ...
Powell; Bordea; Wojnarowska; Farrell; Morris (1999-09-01). "Benign familial Degos disease worsening during immunosuppression". ...
Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself ... A person who is undergoing immunosuppression, or whose immune system is weak for some other reasons (chemotherapy or HIV), is ... Non-deliberate immunosuppression can occur in, for example, ataxia-telangiectasia, complement deficiencies, many types of ... "Immunosuppression: Overview, History, Drugs". 2017-01-06. Cite journal requires ,journal= (help) "NCI Dictionary of Cancer ...
Chemotherapy can produce major immunosuppression in people with cancer and one study shows that 21-33% of cancer patients ...
Immunosuppression is the dampening of the bodys ability to ward off disease and infection. It can be induced deliberately, or ... How is immunosuppression diagnosed and treated?. Immunosuppression may be easily seen from abnormalities in a blood test, ... What are the causes of immunosuppression?. Immunosuppression may be caused by a number of systemic illnesses. These include, ... In some cases, immunosuppression may also be deliberately induced. This induction may be necessary for therapeutic ...
Disclaimer: The information provided on HealthWorld Online is for educational purposes only and IS NOT intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek professional medical advice from your physician or other qualified healthcare provider with any questions you may have regarding a medical condition ...
... many biologic medications available provided immunosuppression. Biologics for immunosuppression include Adalimumab, ... Biologics for immunosuppression (often called "biologics" or "biological therapy" or "biological drugs") are a class of ...
Even after a liver transplant, patients can often experience a recurrence of hepatitis C. How should it be treated in this setting?
Video Tag: Immunosuppression. Chair: B. Fernando Santos, MD Faculty: Peter Muscarella, MD and Ezra Teitelbaum, MD Laparoscopic ... immunosuppression, infection, inflammation, infuser, injury, instruments, intervention, intraoperative cholangiography, ...
Is a treatment strategy of combined immunosuppression safe and effective in those 60 and over? ... Early combined immunosuppression (n = 910). Conventional management (n = 138). Early combined immunosuppression (n = 173). ... Early Combined Immunosuppression may be Effective and Safe in Older Patients With Crohns Disease. Post Hoc Analysis of REACT. ... A major concern with the use of combined immunosuppression in older adults is the risk of serious infections. However, it is ...
... but requires simultaneous immunosuppression to avoid allograft rejection. In this issue of the JCI, Monti et al. report that ... Immunosuppression in islet transplantation J Clin Invest. 2008 May;118(5):1625-8. doi: 10.1172/JCI35639. ... Islet transplantation can temporarily cure type 1 diabetes mellitus (T1DM) but requires simultaneous immunosuppression to avoid ...
Study discovers a mechanism that inhibits tumor growth in skin cancer by switching the immunosuppressive environment to an immunosupportive one.
Immunosuppression underlies resistance to anti-angiogenic therapy. Massachusetts General Hospital. Journal. Journal of Clinical ... Immunosuppression underlies resistance to anti-angiogenic therapy Mass. General study identifies role of non-classical ...
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.. Townsley DM1, Scheinberg P1, Winkler T1, Desmond R1, ... In patients with aplastic anemia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor ...
Osteopontin controls immunosuppression in the tumor microenvironment. Michael R. Shurin Departments of Pathology and Immunology ...
Compare risks and benefits of common medications used for Immunosuppression. Find the most popular drugs, view ratings, user ... About Immunosuppression: Immunosuppression is a disorder or condition where the immune response is reduced or absent. ... Drugs Used for Immunosuppression. The following list of medications are in some way related to, or used in the treatment of ...
BACH2 promotes immunosuppression within tumors. (A and B) Growth of subcutaneous (A) B16 and (B) EL-4 tumors in littermate ... The transcription factor BACH2 promotes tumor immunosuppression. Rahul Roychoudhuri,1,2 Robert L. Eil,1 David Clever,1 ... BACH2 suppresses adaptive immunity to promote immunosuppression within tumors. CD4+ and CD8+ T cells form a key component of ... This led us to ask whether Treg-dependent tumor immunosuppression mediated by BACH2 is caused by suppression of CD8+ T cells or ...
... will be hosting a live symposium on immunosuppression entitled, The Immunosuppression Balancing ... CME Outfitters (CMEO) hosted a live symposium on immunosuppression entitled, The Immunosuppression Balancing Act: Preserving ... CME Outfitters hosted live symposium featuring nationally-renowned experts on immunosuppression at a national transplant ... Esteemed Faculty Presented Latest Evidence on Immunosuppression in CME Outfitters Live Symposium. ...
Mariem Hadj Dahmane, Sarra Zairi, Mouna Attia, Mahdi Abdenadher, Hazem Zribi, Imen Bouassida, Amira Dridi, Aida Ayadi, Amna Brahem, Taher Mestiri, Khawla Ben Miled, Faouzi Mezni, Adel Mrghli ...
pulmonary immunosuppression. Early life exposure to fine particulate matter (PM) in air is associated with acute and chronic ... In utero ultrafine particulate matter exposure causes offspring pulmonary immunosuppression. Kristal A. Rychlik, Jeremiah R. ... In utero ultrafine particulate matter exposure causes offspring pulmonary immunosuppression. Kristal A. Rychlik, Jeremiah R. ... 2014) Early-life exposure to combustion-derived particulate matter causes pulmonary immunosuppression. Mucosal Immunol 7:694- ...
Promethazine: results of triple-drug immunosuppression for kidney transplantation.. Orłowski T, et al. Transplant Proc. 1987. ...
Avoiding Immunosuppression for Islet Transplantation: Use of Protective Biomaterials. Alexander, M., Nguyen, H., Flores, A., Li ... However, the immunosuppression. required for transplantation has the cytotoxic effect on pancreatic islets, and. thus limiting ... toxicity of immunosuppression, immune rejection, and inflammatory response. We will. evaluate the mechanisms of these ...
... or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects. ... and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity. ... 4. Site-Specific Immunosuppression in VCA. The skin is the largest organ in the body [1, 38] and is a physical and ... Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential. Jonas T. Schnider. ,1 ...
This study investigates an alternative to permanent or temporary immunosuppression using a rat model with nerve transplants ... Peripheral Nerve Transplantation: The Effects of Predegenerated Grafts and Immunosuppression. Thomas E. Trumble ... or long-term immunosuppression. The animals in the experimental groups received cyclosporin-A, predegencrated grafts, both, or ... Allograft groups with short-term immunosuppression with cyclosporin-A did as well as isograft groups, and isograft groups with ...
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) (NIPALS2013). The safety and scientific validity of this study is the ... An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph ...
Immunosuppression by Leukemia Viruses. XI. Effect of Friend Leukemia Virus on Humoral Immune Competence of Leukemia-Resistant ... question to the cellular site of action of immunosuppressive tumor viruses and the relationship between immunosuppression and ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.. See eligibility criteria ...
Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic ... COPASI file of Shariatpanahi2018 - Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells ... SBML L2V4 Representation of Shariatpanahi2018 - Mathematical modeling of tumor-induced immunosuppression by myeloid-derived ... With comment: Import of Shariatpanahi2018 - Mathematical modeling of tumor-induced immunosuppression by myeloid-derived ...
Chemotherapy and Immunosuppression. Chemotherapeutic agents should be used under appropriate circumstances, such as for an ...
The profound immunosuppression we observe in PBLs from infants probably contributes to the morbidity and mortality observed in ... Here we report an in vivo model for the study of MV-induced immunosuppression. Human peripheral blood leukocytes (PBLs) grafted ... immunosuppression is dependent on the involvement of live virus and is dramatically more severe for PBLs obtained from newborns ... The main cause of morbidity and mortality is virus-induced immunosuppression of lymphocyte function, which allows secondary ...
... Josep M. Griny . Servei de Nefrologia. Hospital de Bellvitge. Ciutat Sanit ria i ... Maintenance immunosuppression The ideal maintenance immunosuppressive regimen is not established. The majority of centers use ... Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a ... Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate ...
Conditions: Chemotherapy, Cirrhosis, Crohns disease, Diabetes, Hepatitis C, HIV, Immunosuppression, Infection, Malnutrition, ... Conditions: Cadmium toxicity, Immunosuppression, Lead toxicity (plumbism). *Supplements: Amino acids, Antioxidants, Garlic ( ... Conditions: Bacterial infection, Birth defects, Chemotherapy, Fungal infection, Immunosuppression, Irradiation, Lactation, ... Conditions: Environmental pollution, Heavy metal toxicity, Immunosuppression, Mercury poisoning. *Supplements: Alpha lipoic ...
  • In this chapter, we will review the variety of technologies used to protect transplanted islets against toxicity of immunosuppression, immune rejection, and inflammatory response. (
  • Since VCAs are non-life-saving procedures, the risks and toxicity of immunosuppression must be carefully balanced against their potential life enhancing benefits in recipients. (
  • 6 To what degree recipient mortality and graft loss can be attributed to these risk factors, to the direct toxicity of immunosuppression, or to cumulative effects of infection and rejection is debated. (
  • Islet transplantation can temporarily cure type 1 diabetes mellitus (T1DM) but requires simultaneous immunosuppression to avoid allograft rejection. (
  • Executive Medical Director, Solid Organ Transplantation Program, University of Minnesota Medical Center) for this 75-minute event to present the latest evidence on antibody-mediated complications, regular monitoring strategies to optimize immunosuppression, and ways to engage patients to promote adherence and improve overall outcomes. (
  • Promethazine: results of triple-drug immunosuppression for kidney transplantation. (
  • Immunosuppression in renal transplantation. (
  • However, the immunosuppression required for transplantation has the cytotoxic effect on pancreatic islets, and thus limiting the long-term efficacy of the transplant. (
  • Intraperitoneal transplantation of rudimentary pancreatic cells from rat embryos into adult diabetic rats normalizes glucose levels and does not require immunosuppression, a Washington University School of Medicine research team reports. (
  • Modern Immunosuppression Regimens in Kidney Transplantation, Current Concepts in Kidney Transplantation Sandip Kapur, IntechOpen, DOI: 10.5772/54092. (
  • LIFT is prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation. (
  • In conclusion, early introduction of everolimus at an adequate exposure level with gradual calcineurin inhibitor (CNI) withdrawal after liver transplantation, supported by induction therapy and mycophenolic acid, is associated with a significant renal benefit versus CNI-based immunosuppression but more frequent BPAR. (
  • With the help of investigators at the Hillman Center for Pediatric Transplantation and around the country, we have designed simple blood tests that may help determine why some patients need more immunosuppression and some need less. (
  • We hypothesize that transplantation of PVPON/TA-encapsulated allogeneic C57BL/6 islets into diabetic NOD mice will prolong graft function and elicit localized immunosuppression. (
  • Our results provide evidence that reducing oxidative stress following allotransplantation of PVPON/TA-encapsulated islets can elicit localized immunosuppression and potentially delay graft destruction in future human islet transplantation studies. (
  • Is there a mortality estimate with the immunosuppression regimen plus transplantation? (
  • Over the last 10 years, there have been important changes in immunosuppression management and strategies for solid-organ transplantation, characterized by the use of new immunosuppressive agents and regimens. (
  • Historically, corticosteroids have been the backbone of immunosuppression after liver transplantation, and corticosteroids are typically started immediately before or during transplantation. (
  • Antibodies against T-cells are also used to induce immunosuppression after liver transplantation. (
  • We wanted to discover whether antibody induction therapy was better or worse than therapy with corticosteroids for induction of immunosuppression after liver transplantation. (
  • In specific, we wanted to establish the role of T-cell specific antibody induction therapy as part of corticosteroid-free immunosuppression after liver transplantation, and to find out which type of T-cell specific antibody induction therapy works best with the fewest adverse effects. (
  • The poster presentation, to be made on June 2 at 5:30pm by Argos' collaborating scientists from the University of Western Ontario, demonstrates that combination therapy with sCD83 can prolong kidney allograft survival in an animal model of transplantation, and that sCD83 attenuates pathological changes in kidney allografts, induces generation of T regulatory cells and inhibits dendritic cell maturation, all of which may contribute to immunosuppression and allograft tolerance. (
  • Most cases, particularly those arising shortly after transplantation, are associated with infection by the herpesvirus Epstein-Barr virus (EBV) in the setting of impaired T-cell function brought about by iatrogenic immunosuppression. (
  • Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. (
  • In addition to systemic illnesses, certain pharmaceuticals and therapeutic interventions can also cause immunosuppression. (
  • Or it could be possible that some medicines that cause immunosuppression affect skin cells and make them more susceptible to cancer development. (
  • Some procedures can cause immunosuppression too. (
  • Furthermore, 10-15% of SAA patients treated with standard immunosuppression will develop an abnormal karyotype in follow-up, with monosomy 7 being most common, which portends progression to myelodysplasia and leukemia. (
  • Effect of tacrolimus derivatives on immunosuppression. (
  • 63% of new renal transplant recipients in the United States receive tacrolimus for primary immunosuppression compared with only 22% in Australia. (
  • In this post hoc analysis of the REACT trial comparing the magnitude of benefit with an algorithmic early combined immunosuppression strategy vs conventional management, we found no difference in older vs younger patients in maintaining corticosteroid-free clinical remission and delaying risk of Crohn's disease-related surgery, hospitalisation and/or serious complications. (
  • As anticipated, a greater percentage of deaths occurred in older patients, but the percentage was not higher in patients in the early combined immunosuppression group compared to the conventional management group in the two age groups. (
  • In the absence of clinical trials specifically focusing on older patients and clear evidence-based guidance, these data provide useful information on the safety and efficacy of a strategy of algorithmic early combined immunosuppression compared to conventional management in older patients with Crohn's disease. (
  • [ 10 , 11 ] The results of this post hoc analysis challenge the notion of 'undertreating' older patients to avoid treatment complications by demonstrating that a strategy of algorithmic early combined immunosuppression may also be effective and safe in older patients with IBD, potentially decreasing corticosteroid use and risk of Crohn's disease-related complications. (
  • In our study, a strategy of early combined immunosuppression was not found to be differentially effective in younger than older patients with Crohn's disease in terms of decreasing risk of serious disease-related complications and hospitalisation. (
  • In patients with aplastic anemia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically significant increases in blood counts in almost half the patients. (
  • Now an Alimentary Pharmacology & Therapeutics study indicates that older patients can be safely and effectively treated with such combined immunosuppression as well. (
  • Among the 1,981 patients in the study, 311 were aged 60 years or older (173 randomized to early combined immunosuppression and 138 to conventional management). (
  • Over 24 months, 10 percent of older patients developed Crohn's disease-related complications (6.4 percent of those in the combined immunosuppression group versus 14.5 percent of those in the conventional management group) and 14 patients died (3.5 percent versus 5.8 percent). (
  • Among the patients who received combined immunosuppression in the study, older patients experienced remission of their disease to a similar extent as those aged under 60 years. (
  • Patients received multiple intramuscular doses without immunosuppression, and M-ATT expression was evaluated in muscle biopsies. (
  • The purpose of this study was to review the imaging findings of nasal septal abscess in 2 patients with immunosuppression. (
  • Two patients with immunosuppression were identified as having a nasal septal abscess, and correlative CT imaging in both patients was evaluated. (
  • Serious complications may occur as a result of the nasal septal abscess, especially in patients with immunosuppression. (
  • Both patients had immunosuppression and were undergoing chemotherapy. (
  • Two areas of advancement for patients and families of children who are undergoing liver transplant recovery are immunologic testing and immunosuppression withdrawal. (
  • These tests may be of benefit to all patients, both those who need less immunosuppression drugs as well as those who have needed more because of past rejection. (
  • indicating that early conversion of immunosuppression from CNI to mTOR-inhibitors after OLT in HCC patients (n=21) with a "high risk" for tumor recurrence results in a tumor recurrence rate of only 19% and a 4-year over all survival of 83% in this group. (
  • From these results, researchers developed a phenotype of hyperinflammation and immunosuppression that consisted of 326 of 477 (68.3%) patients with high hs-CRP and elevated sPD-L1 levels. (
  • In a landmark study, investigators from Edmonton reported that glucocorticoid-free immunosuppression, islets transplanted from two to four donors, and improved islet isolation methods restored long-term insulin independence in seven consecutive patients ( 13 , 14 ). (
  • Utilize emerging biomarker assessments to risk stratify patients for enrollment and randomization to determine timing of protocol-specified immunosuppression change/increase/decrease, and as surrogate end points ( e.g ., blood genomic profiling, molecular assessment of kidney transplant biopsy tissue, urinary chemokines and mRNA, blood donor-derived cell-free DNA). (
  • In the present report, we show that, during acute HIV-1 infection, immunosuppression of uninfected T cells is governed by the cytokine IFNα and by the HIV-1 Tat protein and that the early production of C-C chemokines by immune cells in response to activation depends on IFNα and Tat and markedly declines as T cell immunosuppression progresses in patients at an advanced stage of infection. (
  • A subset of CCI patients will develop the persistent inflammation, immunosuppression, and catabolism syndrome (PICS), and these individuals are predisposed to a poor quality of life and indolent death. (
  • We aimed to assess whether immunosuppression preserves renal function in patients with idiopathic membranous nephropathy with declining renal function. (
  • A person who is undergoing immunosuppression, or whose immune system is weak for some other reasons (chemotherapy or HIV), is said to be immunocompromised. (
  • Importantly, skin has been shown to be the most immunogenic constituent of certain VCA [ 1 ] mandating long-term immunosuppression for graft survival. (
  • Despite evolving clinical experience and progress in the understanding of the biology of VCA, one of the main factors preventing wider acceptance or routine clinical application is the associated adverse effects of long-term immunosuppression. (
  • Predegenerated nerve allografts will allow for greater neurologic recovery than standard nerve allografts avoiding the complications of immunosuppression, but the level of recovery is less than that of recipients of nerve allografts with immunosuppression. (
  • However, there is mounting evidence that a significant percentage of liver transplant recipients can maintain a healthy, functioning transplant without ongoing immunosuppression. (
  • Eligible recipients will be placed on a modified medication schedule to gradually decrease their immunosuppression medication slowly over a 9- to 12-month period, during which time they will be closely monitored by study staff. (
  • In the absence of systemic immunosuppression, diabetic recipients containing PVPON/TA-encapsulated islets maintained euglycemia and delayed graft rejection significantly longer than those receiving nonencapsulated islets. (
  • In general, deliberately induced immunosuppression is performed to prevent the body from rejecting an organ transplant. (
  • CME Outfitters (CMEO) hosted a live symposium on immunosuppression entitled, The Immunosuppression Balancing Act: Preserving Long-Term Allograft Function for Optimal Patient Outcomes, on Tuesday, May 2, 2017, as part of a national conference for clinicians in transplant medicine being held in Chicago, IL. (
  • Rational clinical regimens for kidney transplant immunosuppression. (
  • The rationale for such site-specific, transplant-targeted delivery of immunosuppression is to reduce systemic exposure and global collateral or end-organ adverse effects. (
  • Deliberately induced immunosuppression is generally done to prevent the body from rejecting an organ transplant , treating graft-versus-host disease after a bone marrow transplant , or for the treatment of auto-immune diseases such as rheumatoid arthritis or Crohn's disease . (
  • Bone marrow etiologies of acquired immunosuppression include either post-transplant immunosuppression, viral disease (eg HIV and AIDS ), or drugs among other causes. (
  • Therapeutic immunosuppression has uses in scientific medicine, which vary from prevention and therapy of organ/bone marrow transplant rejection to organization of autoimmune and inflammatory disorders. (
  • Removal of the spleen, bone marrow ablation, and organ transplant are all associated with immunosuppression. (
  • When immunoprofiles of human blood infected with ZIKV were compared, a classical/intermediate monocyte-mediated M1-skewed inflammation by the African-lineage ZIKV infection was observed, in contrast to a non-classical monocyte-mediated M2-skewed immunosuppression by the Asian-lineage ZIKV infection. (
  • In sum, the findings indicated that fermented red ginseng could reduce immunosuppression and inflammation by suppressing macrophage activation and regulating Th1 and Treg cell differentiation. (
  • Individuals with persistent biomarkers of inflammation and immunosuppression had a higher risk of readmission and death due to cardiovascular disease and cancer compared with those with normal circulating biomarkers," Sachin Yende, MD , of the VA Pittsburgh Healthcare System and the University of Pittsburgh and colleagues wrote in their study. (
  • corticosteroids induce immunosuppression that is claimed to be caused by HIV, with lowered CD4 counts and sparing of CD8 cells as well as sparing of antibody production. (
  • Dr. Joseph Murray of Brigham and Women's Hospital, was given the Nobel Prize in Physiology or Medicine in 1990 for work on immunosuppression. (
  • Dr. Joseph Murray of Harvard Medical School and chief plastic surgeon at Children's Hospital Boston from 1972-1985 was awarded the Nobel Prize in Physiology or Medicine in 1990 for his work on immunosuppression. (
  • The suppression of the body's innate ability to ward off disease and infection is known as immunosuppression. (
  • This is known as immunosuppression, but you may also see it referred to as immunocompromised or immunodeficiency. (
  • Human peripheral blood leukocytes (PBLs) grafted onto mice with severe combined immunodeficiency disease (SCID mice) to create hu-PBLS-SCID mice produce human IgG that is suppressed by MV infection, immunosuppression is dependent on the involvement of live virus and is dramatically more severe for PBLs obtained from newborns than PBLs from adults. (
  • Specifically, Asian-lineage ZIKV infection of pregnant women's blood led to an exacerbated M2-skewed immunosuppression of non-classical monocytes in conjunction with a global suppression of type I interferon-signalling pathway and an aberrant expression of host genes associated with pregnancy complications. (
  • The data presented here provide evidence that immunosuppression in addition to infection of target tissues and allergic reactions (including types 3 and 4) contributes to the pathogenesis of brucellosis. (
  • And as a result of the way their immune systems react to infections, people with immunosuppression are more likely to need antibiotics or hospital treatment for an infection than those whose immune systems are working normally. (
  • The clinical corollary is the immunosuppression of uninfected T cells and the decline in C-C chemokine release found at advanced stages of HIV-1 infection paralleling rising levels of IFNα and extracellular Tat. (
  • Immunosuppression of uninfected cells may be initiated in vitro by CD4 + T cell anergy ( 8 ), which in HIV-1 infection may be caused by an effect of the HIV-1 gp120 on these cells ( 7 , 9 , 10 ). (
  • Furthermore, immunosuppression secondary to rituximab administration can lead to reactivation of hepatitis B infection. (
  • Of note, immunosuppression resulting from the administration of these drugs opens the door to infection with Listeria monocytogenes, a foodborne pathogen that can cause fetal death in pregnant women. (
  • Choosing the proper immunosuppression for a patient involves balancing the risk of immunologic graft injury against the risks of infection and malignancy. (
  • These findings support 2 mechanisms of lymphomagenesis, one predominantly of primary EBV infection in the context of intense immunosuppression, and another of dysregulated lymphoid proliferation in a prolonged immunosuppressed state. (
  • Lymphocyte counts recover shortly after the disappearance of measles-associated rash, but immunosuppression can persist for months to years after infection, resulting in increased incidence of secondary infections. (
  • Using B cell receptor (BCR) sequencing of human peripheral blood lymphocytes before and after MeV infection, we identified two immunological consequences from measles underlying immunosuppression: (i) incomplete reconstitution of the naïve B cell pool leading to immunological immaturity and (ii) compromised immune memory to previously encountered pathogens due to depletion of previously expanded B memory clones. (
  • Smallpox infection and death rates with different levels of residual vaccine immunity including and excluding immunosuppression in model of smallpox transmission, by age group, New York, NY, USA, and Sydney, Australia. (
  • Tanshinone IIA attenuates sepsis-induced immunosuppression and improves survival rate in a mice peritonitis model. (
  • The importance of sepsis-induced immunosuppression and its contribution to mortality has recently emerged. (
  • Specifically, the report reveals that in the late stage of sepsis, HMGB1, or the "high mobility group box 1" protein, might be a target for future therapies because the protein plays a key role in the development of post-sepsis immunosuppression and sepsis-induced dysfunction of neutrophils (white blood cells). (
  • Therapeutic interventions for sepsis are limited to the use of antibiotics and fluid resuscitation, since specific pharmacological treatment is not available to prevent or correct sepsis-induced immunosuppression," said Jean-Marc Tadié, M.D., Ph.D., a researcher involved in the work from the Department of Infectious Diseases and Medical Intensive Care Unit at the Pontchaillou University Hospital, Rennes, France. (
  • Sepsis-induced immunosuppression that covers both innate and adaptive immune systems acts as a predominant cause of late mortality due to recurrent infections ( 5 ). (
  • People in remission from cancer who require immunosuppression are not more likely to experience a recurrence. (
  • Immunosuppression is weaned as part of our ongoing clinical efforts to minimize the complications of immune suppressants. (
  • Here, we evaluated and compared the efficacy of two different doses (50 and 100 mg/kg body weight, given orally for 30 consecutive days) of Egyptian sweet marjoram leaf powder (MLP) and marjoram leaf aqueous extract (MLE) in alleviating the genotoxicity, immunosuppression and other complications induced by CP in non-tumour-bearing albino rats. (
  • Immunosuppression may be caused by a number of systemic illnesses. (
  • Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may reduce the need for systemic immunosuppression with its adverse effects. (
  • Hypothetically, site-specific graft immunosuppression could facilitate minimization of overall dosing, frequency, and duration of systemic immunosuppression and also help reduce the number of systemic drugs required for desired efficacy and improved graft survival. (
  • These results present strong evidence for an active systemic immunosuppression in pancreatic cancer, as shown by elevated IL-10 and TGF-β1/2 serum levels as well as the presence of disseminated tumor cells. (
  • These observations are pertinent to the general question to the cellular site of action of immunosuppressive tumor viruses and the relationship between immunosuppression and the neoplastic properties of the RNA viruses. (
  • This is a ODE-based mathematical model featuring equations describing the dynamics of tumor cells, cytotoxic T cells, natural killer cells, and myeloid-derived suppressor cells (MDSCs) that together describe the tumor-induced immunosuppression caused by MDSCs. (
  • In this study, we present a mathematical model based on ordinary differential equations (ODE) to describe tumor-induced immunosuppression caused by MDSCs. (
  • Tumor-induced immunosuppression is a common obstacle for cancer treatment. (
  • Click on the mechanisms of tumor-derived exosome (TEX)-mediated immunosuppression listed on the left below under Explore Pathways to see the specific TEX-associated molecules that are involved in each mechanism and an explanation of how they negatively regulate the immune response. (
  • Although it has been shown that tumor-derived interleukin (IL)-18 participates in the PD-1-dependent tumor progression in NK cell-controlled cancers, the mechanistic cues underlying this immunosuppression remain unknown. (
  • 2017. (
  • Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the dosing, frequency, and duration of overall immunosuppression in VCA with minimization or elimination of long-term drug-related toxicity. (
  • Of therapeutic relevance, the authors showed that propranolol, a commonly prescribed β-blocker, can reduce MDSC immunosuppression and enhance the effect of other cancer therapies. (
  • This book brings forward significant growth in the area of molecular mechanisms and active therapeutic aspects used for immunosuppression in different human disease situations. (
  • Immunosuppression Withdrawal: Is It Possible? (
  • Here, we provide a comprehensive update on clinical features, diagnostics, consequences on immunity and immunosuppression, and clinical outcomes. (
  • However, a deliberate immunosuppression is still necessary, such as to prevent rejection of organ transplants . (
  • Immunosuppression is a reduction of the activation or efficacy of the immune system. (
  • Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions. (
  • Immunosuppression involves an act that reduces the activation or efficacy of the immune system . (
  • In some cases, immunosuppression can be temporary, and those affected may find their immune system returns to normal after a while. (
  • Any act which weakens the efficiency of immune system is classified under Immunosuppression. (
  • Immunosuppression means that your immune system is not functioning as it should. (
  • Immunosuppression also increases the risk of cancer, because the immune system helps protect the body from cancer. (
  • In this study we examined the effects of Tanshinone II-A (TSN), a widely used traditional Chinese medicine, on immunosuppression in experimental peritonitis induced septic mice. (
  • They conducted the study in mice with cyclophosphamide-induced immunosuppression and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. (
  • Brucellosis in mice results in a distinct immunosuppression which may be abrogated by immunomodulators, such as levamisole, bestatin, interleukin-2 (IL-2) and Polyporus umbellatus. (
  • C3H mice chronically infected with LCM virus were found to be lethally affected by small doses of immunosuppression which caused bone marrow aplasia but had no effect on the amount of virus carried by the mouse. (
  • Over half of the chronic LCM carrier SWR/J mice treated with cyclophosphamide for 6 mo had total anti-LCM humoral immunosuppression, but showed no change in the level of virus carried. (
  • Oral administration of GP-EX to mice prevented EFS stress-induced immunosuppression as determined by the lymphoid organ (thymus and spleen) weight and cellularity. (
  • Lee, C.K. Restoration of Electric Footshock-Induced Immunosuppression in Mice by Gynostemma pentaphyllum Components. (
  • Lachmann G, von Haefen C, Kurth J, Yuerek F, Spies C. Innate immunity recovers earlier than acquired immunity during severe postoperative immunosuppression. (
  • However, the recovery of immune cells focusing on differences between innate and acquired immunity during severe postoperative immunosuppression is not investigated. (
  • Factors that negatively affected sustained virologic response rates included HIV-related immunosuppression, HCV RNA load, severity of liver disease and suboptimal DAA-based regimens. (
  • They also discovered how an antibody can block this assembly and the immunosuppression it induces downstream. (
  • HIV type 1 (HIV-1) not only directly kills infected CD4 + T cells but also induces immunosuppression of uninfected T cells. (
  • In contrast, malignant clonal evolution is rare in complete responders to immunosuppression. (
  • The profound immunosuppression we observe in PBLs from infants probably contributes to the morbidity and mortality observed in infants vaccinated with measles virus. (
  • Weaning of immunosuppression is individually tailored to each patient. (
  • Biologics for immunosuppression (often called "biologics" or "biological therapy" or "biological drugs") are a class of immunosuppressive drugs which chemically are biopharmaceutical treatments. (
  • In some cases, immunosuppression may also be deliberately induced. (
  • The main cause of morbidity and mortality is virus-induced immunosuppression of lymphocyte function, which allows secondary infections. (
  • Furthermore, the production of C-C chemokines in response to immune cell activation, initially enhanced by IFNα and Tat, ultimately is inhibited by these proteins in parallel with their induction of immunosuppression. (
  • Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-dependent fashion leading to immunosuppression by interleukin 10 induction. (
  • Graft failure occurred in 13.1%, in all cases after termination of immunosuppression with MMF or CSA. (
  • Herpes recurrence occurred in 31.8%, in 5 cases during and in 18 cases after immunosuppression, and caused 18.2% of graft failure. (
  • In 5 cases immune rejection was noticed during and in 18 cases after immunosuppression. (
  • However, many immunosuppression disorders are a result of a problem with the immune system's white blood cells, which are important because they attack and destroy pathogens. (
  • This assumption is also favored by a series of experimental results ( 2 - 4 , 7 ) that showed that the decline in CD4 + T cells also importantly involves immunosuppression and apoptosis of uninfected T cells, thereby challenging the view of a simple killing of infected T cells by the virus and the rapid replacement of these cells ( 5 ). (
  • Thus, extracellular Tat may act as a viral toxin on uninfected T cells ( 27 ) and trigger immunosuppression ( 28 , 29 ) and apoptosis of these uninfected cells ( 30 , 31 ). (
  • In particular, postoperative immunosuppression comprises decreased numbers of natural killer (NK) cells, T lymphocytes, as well as an impaired function of T lymphocytes and monocytes including a suppressed expression of human leukocyte antigen-D related on monocytes (mHLA-DR) [ 1 , 13 - 19 ]. (
  • The explanation for this is that while "biologic" or "biopharmaceutical" refers to the chemical composition of medications which might be used to treat a range of medical conditions, when the term "biologic" became popular, many biologic medications available provided immunosuppression. (
  • Non-deliberate immunosuppression can occur in, for example, ataxia-telangiectasia, complement deficiencies, many types of cancer, and certain chronic infections such as human immunodeficiency virus (HIV). (
  • Human immunodeficiency virus (HIV) can cause AIDS, another cause of immunosuppression. (